Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.53 |
| ▸ | PPARA | Q07869 | 12/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773871 | 0.94 | SLC6A2 (0.52) | PPARGPPARALDHASLC6A2SLC6A3 | |
| SCHEMBL15454448 | 0.92 | SLC6A2 (0.50) | PPARGPPARALDHASLC6A2SLC6A3 | |
| SCHEMBL6712771 | 0.88 | PPARG (0.59) | PPARGPPARALDHASLC6A2SLC6A3 | |
| SCHEMBL9317096 | 0.85 | LDHA (0.52) | LDHAACACB | |
| SCHEMBL3778897 | 0.84 | ACACB (0.43) | PPARGPPARALDHASLC6A2SLC6A3 | |
| SCHEMBL10756180 | 0.82 | SLC7A5 (0.63) | LDHASLC6A2 | |
| SCHEMBL9833991 | 0.82 | ALPI (0.61) | LDHA | |
| SCHEMBL27300438 | 0.82 | ALPI (0.61) | LDHA | |
| SCHEMBL1532407 | 0.82 | ALPI (0.61) | LDHA | |
| SCHEMBL901733 | 0.81 | EPHX2 (0.50) | PPARGPPARAACACBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116287032-A | Method for preparing 3-oxo-ethyl butyrate derivative by reacting aromatic aldehyde with ethyl acetoacetate under enzyme catalysis | 岭南师范学院 | 2023-06-23 | — | — | CN | disclosed |
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
| EP-1395590-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-A]INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094830-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | PPARG 729/4885PPARA 620/4885LDHA 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.